Conclusions
Pending the development of an effective vaccine against COVID-19, and the development of direct antivirals, a therapeutic hope may arise from the use of PT taken from patients treated with COVID-19. Currently, based on the successes achieved against past epidemics, such as Sars-Cov and MERS, similar to the current Sars-Cov-2, and based on the first efficacy data from early studies, it is expected that human plasma therapy with COVID-19 cured patients will be an effective and safe therapy for both treatment and post-exposure prophylaxis. However, the importance and validity of this therapeutic treatment will be defined by the various ongoing clinical studies.
MAIN STATEMENTS
I, the undersigned, Francesco Ferrara and any other author, declare that:
Regards
The authors